W. L. Gore & Associates, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$78.4M
Doctors Paid
22,781
Transactions
172,532
2024 Total
$9.5M
Payment Breakdown by Category
Research$35.8M (45.7%)
Consulting$15.1M (19.2%)
Food & Beverage$8.6M (10.9%)
Travel$5.2M (6.6%)
Royalty/License$12,563 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $35.8M | 8,428 | 45.7% |
| Consulting Fee | $15.1M | 5,356 | 19.2% |
| Honoraria | $8.9M | 2,017 | 11.3% |
| Food and Beverage | $8.6M | 136,494 | 10.9% |
| Travel and Lodging | $5.2M | 17,075 | 6.6% |
| Education | $2.2M | 3,029 | 2.9% |
| Grant | $1.5M | 68 | 2.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $840,000 | 6 | 1.1% |
| Charitable Contribution | $170,966 | 43 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $82,461 | 14 | 0.1% |
| Royalty or License | $12,563 | 2 | 0.0% |
Payments by Type
General
$42.5M
164,104 transactions
Research
$35.8M
8,428 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Evaluation of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms | $4.4M | 0 | 968 |
| GORE CARDIOFORM ASD Occluder Clinical Study: A Study to evaluate safety and efficacy in the treatment of transcatheter closure of ostium secundum atrial septal defects (ASDs) | $4.1M | 0 | 546 |
| Evaluation of the GORE TAG Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta | $4.1M | 0 | 883 |
| Gore Research and Development | $3.3M | 0 | 164 |
| GREAT Global Registry for Endovascular Aortic Treatment | $2.6M | 0 | 689 |
| GORE CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with Patent Foramen Ovale (PFO): the REDUCE Post Approval Study | $2.1M | 0 | 590 |
| GORE EXCLUDER Conformable Endoprosthesis | $2.0M | 0 | 772 |
| Evaluation of the GORE TAG TSSB-LSA Endoprosthesis in the Treatment of Proximal Descending Thoracic Aortic Aneurysms | $1.3M | 0 | 256 |
| Evaluation of the GORE Ascending Stent Graft in the Treatment of Isolated Lesions, Pseudoaneurysms, and Penetrating Aortic Ulcers of Ascending Aorta and Aortic Arch | $817,551 | 0 | 70 |
| GORE CARDIOFORM Septal Occluder Migraine Clinical Study: A Study to evaluate the safety and efficacy of transcatheter closure of patent foramen ovale for relief of migraine headaches | $810,184 | 0 | 138 |
| GORE EXCLUDERConformable Endoprosthesis | $771,924 | 0 | 201 |
| Evaluation of the GORE EXCLUDER Iliac Branch Endoprosthesis for the Treatment of Common Iliac Artery Aneurysms or Aorto-iliac Aneurysms | $770,650 | 0 | 311 |
| TAMBE - Initial Feasibility Assessment of the GORE EXCLUDER Juxtarenal and Thoracoabcominal Branch System in the Treatment of Crawford Type IV Thoracoabdomial and Juxtarenal Aortic Aneurysms | $708,617 | 0 | 119 |
| GORE Carotid Stent Clinical Study for the treatment of carotid artery stenosis in patients at increased risk for adverse events from carotid endarterectomy - The Gore SCAFFOLD Clinical Study | $651,418 | 0 | 320 |
| GORE CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with Patent Foramen Ovale PFO the REDUCE Post Approval Study | $542,497 | 0 | 155 |
| Evaluation of the GORE TAG TSSB-BCA Endoprosthesis in the Treatment of Aortic Arch Aneurysms | $524,379 | 0 | 94 |
| GORE SYNECOR Study: A study to evaluate mid-term performance in the treatment of ventral, incisional, parastomal, and inguinal hernias | $493,076 | 0 | 28 |
| GORE HELEX Septal Occluder / GORE Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Confirmed TIA in Patients with Patent Foramen Ovale (PFO) | $470,836 | 0 | 293 |
| Evaluation of the GORE TAG TSSB LSA Endoprosthesis in the Treatment of Proximal Descending Thoracic Aortic Aneurysms | $453,716 | 0 | 145 |
| GORE ENFORM Biomaterial Product Study: A study to describe biomaterial multi-use performance | $393,715 | 0 | 57 |
| Post-Market Evaluation of the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface for Treatment of In-Stent Restenosis in the Superficial Femoral Artery | $390,794 | 0 | 169 |
| GORE Septal Occluder Clinical Study: A Study to evaluate safety and efficacy in the treatment of transcatheter closure of ostium secundum atrial septal defects (ASDs) | $332,762 | 0 | 160 |
| A Comparison of the GORE VIABAHN VBX Balloon Expandable Endoprosthesis (VBX) to Bare Mental Stenting for Patients with Complex Iliac Occlusive Disease | $331,659 | 0 | 47 |
| Gore CARDIOFORM Septal Occluder and Antiplatelet Medical Management for the Reduction of Recurrent Stroke in Patients with Patent Foramen Ovale (PFO) | $256,526 | 0 | 76 |
| Evaluation of the GORE TAG Thoracic Branch Endoprosthesis in the Treatment of DeBakey Type I/II Aortic Dissection | $254,082 | 0 | 88 |
| Assessment of the GORE EXCLUDER Conformable AAA Endoprosthesis (CEXC Device) in the Treatment of Abdominal Aortic Aneurysms | $241,345 | 0 | 83 |
| GORE CARDIOFORM ASD Occluder Clinical Study A Study to evaluate safety and efficacy in the treatment of transcatheter closure of ostium secundum atrial septal defects ASDs | $237,550 | 0 | 107 |
| Evaluation of the GORE EXCLUDER Throacoabdominal Branch Endoprothesis in the Treatment of Throacoabdominal and Pararenal Aortic Aneurysms | $234,317 | 0 | 95 |
| Gore Research & Development | $229,596 | 0 | 7 |
| Evaluation of the GORE PV1 for Replacement of the Pulmonary Valve and Reconstruction of Right Ventricular Outflow Tract (RVOT) | $229,447 | 0 | 28 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2020 |
|---|---|---|---|---|
| Dr. Sapan Desai, M.d., Ph.d., Mba, M.D., PH.D., MBA | Surgery | Arlington Heights, IL | $1.2M | $0 |
| Michael Dake, Md, MD | Diagnostic Radiology | Stanford, CA | $677,213 | $0 |
| Dr. Darren Schneider, Md, MD | Vascular Surgery | Philadelphia, PA | $626,345 | $0 |
| Joseph Bavaria, Md, MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Allentown, PA | $611,802 | $0 |
| Dr. Matthew Goldblatt, Md, MD | Surgery | Milwaukee, WI | $522,056 | $0 |
| Brant Heniford, Md, MD | Surgical Oncology | Charlotte, NC | $499,863 | $0 |
| Esen Akpek, M.d, M.D | Ophthalmology | Baltimore, MD | $470,876 | $0 |
| Ross Milner | Vascular Surgery | Chicago, IL | $468,160 | $0 |
| John Fischer, Md, MD | Plastic Surgery | Philadelphia, PA | $455,437 | $0 |
| Michael Marin, Md, MD | Surgery | New York, NY | $441,819 | $0 |
| Dr. Sukgu Han, M.d, M.D | Vascular Surgery | Los Angeles, CA | $379,608 | $0 |
| Cheguevara Afaneh, M.d, M.D | Student in an Organized Health Care Education/Training Program | New York, NY | $378,218 | $0 |
| Gagan Singh, M.d, M.D | Cardiovascular Disease | Sacramento, CA | $350,476 | $0 |
| Takao Ohki | Vascular Surgery | Lake Success, NY | $345,366 | $0 |
| Dr. Fernando Fleischman, Md, MD | Surgery | Los Angeles, CA | $305,468 | $0 |
| Matthew Gillespie, M.d, M.D | Pediatrics | Philadelphia, PA | $298,136 | $0 |
| Dr. Robert Rhee, Md, MD | Vascular Surgery | Brooklyn, NY | $284,971 | $0 |
| William Cobb, M.d, M.D | Surgery | Greenville, SC | $282,225 | $0 |
| Dr. Mark Bates, Md, MD | Vascular & Interventional Radiology | Charleston, WV | $278,062 | $0 |
| Dr. Garth Jacobsen, Md, MD | Surgery | San Diego, CA | $274,383 | $0 |
| Unknown Provider | — | — | $269,486 | $0 |
| Dr. Marcos Michelotti, M.d, M.D | Surgery | Loma Linda, CA | $260,144 | $0 |
| Steven Bolling, Md, MD | Surgery | Ann Arbor, MI | $243,814 | $0 |
| Thomas Smith, M.d, M.D | Internal Medicine | Sacramento, CA | $237,113 | $0 |
| Mr. Barry Katzen, Md, MD | Diagnostic Radiology | Miami, FL | $233,224 | $0 |
Ad
Top Products
- Product in Development $38.0M
- EXCLUDER AAA Endoprosthesis $2.3M
Associated Products (72)
- Product in Development $42.1M
- EXCLUDER AAA Endoprosthesis $2.3M
- VIABAHN VBX Balloon Expandable Endoprosthesis $2.3M
- GORE CARDIOFORM Septal Occluder $2.1M
- GORE-TEX Vascular Graft $1.8M
- SYNECOR Biomaterial $1.6M
- TAG Thoracic Endoprosthesis $1.6M
- VIABAHN Endoprosthesis $1.5M
- Conformable TAG Thoracic Endoprosthesis $1.4M
- CARDIOFORM Septal Occluder $1.4M
- GORE EXCLUDER AAA Endoprosthesis $1.3M
- SEAMGUARD Bioabsorbable Staple Line Reinforcement $1.3M
- ACUSEAL Vascular Graft $1.3M
- BIO-A Tissue Reinforcement $1.1M
- GORE SYNECOR Biomaterial $1.1M
- GORE TAG Thoracic Endoprosthesis $1.1M
- GORE VIABAHN VBX Balloon Expandable Endo $988,702
- EXCLUDER Iliac Branch Endoprosthesis $964,772
- GORE BIO-A Tissue Reinforcement $956,750
- GORE ENFORM Preperitoneal Biomaterial $948,315
- EXCLUDER Conformable AAA Endoprosthesis with Active Control $859,193
- GORE TAG Thoracic Branch Endoprosthesis $783,254
- BIO-A Tissue Reinforcement $781,393
- VIATORR TIPS Endoprosthesis $742,034
- C3 Delivery System $740,336
- Vascular Graft $736,155
- GORE SEAMGUARD Bioabsorbable Staple Line Reinforce $704,833
- GORE EXCLUDER Iliac Branch Endoprosthesis $685,176
- Carotid Stent $642,431
- HELEX Septal Occluder $516,249
- GORE VIABAHN Endoprosthesis $485,091
- GORE TAG Conformable Thoracic Stent Graft $481,343
- GORE CARDIOFORM ASD Occluder $443,712
- GORE TAG Conformable Thoracic Endoprosthesis $411,207
- GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $392,282
- SEAMGUARD Staple Line Reinforcement $360,028
- GORE VIABAHN Endoprosthesis with Heparin $358,951
- VIABAHN Endoprosthesis with PROPATEN Bioactive Surface $292,169
- VIABAHN Endoprosthesis with Heparin Bioactive Surface $275,946
- GORE DUALMESH Biomaterial $262,256
- VIATORR Endoprosthesis $233,423
- PROPATEN Vascular Graft $190,818
- Conformable GORE TAG Thoracic Endoprosthesis $183,546
- SEAMGUARD $167,302
- GORE Septal Occluder $150,956
- GORE ENFORM Biomaterial $146,528
- GORE ACUSEAL Vascular Graft $118,431
- GORE VIATORR TIPS Endoprosthesis $107,316
- GORE TIGRIS Vascular Stent $99,118
- GORE PROPATEN Vascular Graft $94,757
- TIGRIS Stent $83,556
- GORE VIABIL Biliary Endoprosthesis $82,688
- GORE DRYSEAL FLEX Introducer Sheath $75,297
- GORE VIABAHN Balloon Expandable Endoprosthesis $70,734
- Stretch Vascular Graft $50,044
- VIATORR TIPS Endoprosthesis w/ Controlled Expansion $41,793
- VIABIL Biliary Endoprosthesis $37,195
- BIO-A Hernia Plug $34,869
- DUALMESH Biomaterial $26,500
- PROPATEN Bioactive Surface $22,491
- Septal Occluder $21,308
- Zipstick Cast Removal Tool $21,185
- Dryseal Flex Sheath $20,354
- BIO-A Hernia Plug $19,388
- GORE Hybrid Vascular Graft $18,958
- ACUSEAL Cardiovascular Patch $16,267
- GORE ACUSEAL Cardiovascular Patch Vascular $14,584
- VIATORR TIPS Endoprosthesis w/ $14,563
- Hybrid Vascular Graft $12,582
- GORE MYCROMESH Biomaterial $10,620
- Balloon Sheath with Dilator $10,366
- Cardiovascular Patch $10,246
Payment Categories
- Food & Beverage $8.6M
- Consulting $15.1M
- Travel & Lodging $5.2M
- Research $35.8M
- Royalties $12,563
About W. L. Gore & Associates, Inc.
W. L. Gore & Associates, Inc. has made $78.4M in payments to 22,781 healthcare providers, recorded across 172,532 transactions in the CMS Open Payments database. In 2024, the company paid $9.5M. The top product by payment volume is Product in Development ($38.0M).
Payments were distributed across 189 medical specialties. The top specialty by payment amount is Surgery ($11.9M to 5,417 doctors).
Payment categories include: Food & Beverage ($8.6M), Consulting ($15.1M), Research ($35.8M), Travel & Lodging ($5.2M), Royalties ($12,563).
W. L. Gore & Associates, Inc. is associated with 72 products in the CMS Open Payments database, including Product in Development, EXCLUDER AAA Endoprosthesis, and VIABAHN VBX Balloon Expandable Endoprosthesis.